KR101840082B1 - 지질 대사 장애의 치료에 유용한 조성물 - Google Patents

지질 대사 장애의 치료에 유용한 조성물 Download PDF

Info

Publication number
KR101840082B1
KR101840082B1 KR1020137028752A KR20137028752A KR101840082B1 KR 101840082 B1 KR101840082 B1 KR 101840082B1 KR 1020137028752 A KR1020137028752 A KR 1020137028752A KR 20137028752 A KR20137028752 A KR 20137028752A KR 101840082 B1 KR101840082 B1 KR 101840082B1
Authority
KR
South Korea
Prior art keywords
dose
policosanol
acid
resveratrol
vitamin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020137028752A
Other languages
English (en)
Korean (ko)
Other versions
KR20140036170A (ko
Inventor
알레아르도 코베레츠
아쉬라프 비르마니
Original Assignee
알파시그마 에스.피.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알파시그마 에스.피.에이. filed Critical 알파시그마 에스.피.에이.
Publication of KR20140036170A publication Critical patent/KR20140036170A/ko
Application granted granted Critical
Publication of KR101840082B1 publication Critical patent/KR101840082B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105Plant extracts, their artificial duplicates or their derivatives
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115Fatty acids or derivatives thereof; Fats or oils
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15Vitamins
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17Amino acids, peptides or proteins
    • A23L33/175Amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • A61K31/122Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415Pyridoxine, i.e. Vitamin B6
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135Compounds containing heavy metals
    • A61K31/714Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/30Zinc; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/16Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/899Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/10Preparation or pretreatment of starting material
    • A61K2236/19Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06Fungi, e.g. yeasts
    • A61K36/062Ascomycota

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020137028752A 2011-05-03 2012-04-24 지질 대사 장애의 치료에 유용한 조성물 Expired - Fee Related KR101840082B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11164526.3 2011-05-03
EP11164526 2011-05-03
PCT/EP2012/057428 WO2012150146A1 (en) 2011-05-03 2012-04-24 Composition useful for the treatment of lipid metabolism disorders

Publications (2)

Publication Number Publication Date
KR20140036170A KR20140036170A (ko) 2014-03-25
KR101840082B1 true KR101840082B1 (ko) 2018-03-19

Family

ID=44645300

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137028752A Expired - Fee Related KR101840082B1 (ko) 2011-05-03 2012-04-24 지질 대사 장애의 치료에 유용한 조성물

Country Status (29)

Country Link
US (1) US9125903B2 (enExample)
EP (1) EP2704734B1 (enExample)
JP (1) JP2014514340A (enExample)
KR (1) KR101840082B1 (enExample)
CN (1) CN103517711B (enExample)
AR (1) AR086231A1 (enExample)
AU (1) AU2012251818B2 (enExample)
CA (1) CA2834173A1 (enExample)
CL (1) CL2013003144A1 (enExample)
CY (1) CY1116612T1 (enExample)
DK (1) DK2704734T3 (enExample)
EA (1) EA025256B1 (enExample)
ES (1) ES2542412T3 (enExample)
HR (1) HRP20150767T1 (enExample)
IL (1) IL229205A (enExample)
ME (1) ME02180B (enExample)
MX (1) MX361038B (enExample)
MY (1) MY176018A (enExample)
NZ (1) NZ617641A (enExample)
PH (1) PH12013502229A1 (enExample)
PL (1) PL2704734T3 (enExample)
PT (1) PT2704734E (enExample)
RS (1) RS54100B1 (enExample)
SG (1) SG194679A1 (enExample)
SI (1) SI2704734T1 (enExample)
SM (1) SMT201500173B (enExample)
UA (1) UA112182C2 (enExample)
WO (1) WO2012150146A1 (enExample)
ZA (1) ZA201309205B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220069174A (ko) * 2020-11-19 2022-05-27 한국식품산업클러스터진흥원 천연 복합물을 포함하는 비만 예방 또는 치료용 조성물

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103202471B (zh) * 2013-04-25 2014-06-11 福建永生活力生物工程有限公司 一种辅助降血脂的保健食品及其制备方法
WO2016193096A1 (en) 2015-05-29 2016-12-08 Givaudan Sa Spray drying
CN105395925A (zh) * 2015-11-27 2016-03-16 杭州海王生物工程有限公司 一种以降血脂为基础的具有降血压和减肥功效的组合物
CN105475580A (zh) * 2016-01-19 2016-04-13 苟春虎 黑青稞降血脂茶(奶茶)
CN105853347A (zh) * 2016-04-01 2016-08-17 海南合瑞制药股份有限公司 一种左卡尼汀的组合物及其制备方法
IT201600075378A1 (it) * 2016-07-19 2018-01-19 Farm Legnani Del Dottor De Zanetti Andrea Integratore alimentare a base di riso rosso fermentato
IT201600078969A1 (it) * 2016-07-27 2018-01-27 Buonamici Gugliemo Integratore alimentare
WO2019018937A1 (en) 2017-07-26 2019-01-31 Yacyshyn Vincent REMOVAL OF CONTAMINANT POLYPHENOLS FROM START LOAD POLYPHENOLS
EP3735296A4 (en) 2018-01-04 2021-09-08 Pure Care Pro Llc NATURAL COMBINED PRODUCTS AND TOTAL BLOOD CHOLESTEROL REGULATION METHODS
US11173187B2 (en) 2018-11-13 2021-11-16 Immortazyme Company Ltd. Concentrated oil-based polyphenol composition and a method of producing the oil-based polyphenol composition
IT201900007002A1 (it) * 2019-05-20 2020-11-20 Angelo Montecuollo Integratore alimentare a base di caffè
CN112056563A (zh) * 2020-09-15 2020-12-11 王胜林 用于修复脂质代谢障碍的营养素组合物及其应用
IT202200003191A1 (it) * 2022-02-21 2023-08-21 Inpha Res S R L Composizione per il controllo delle iperlipidemie
CN119424573B (zh) * 2024-02-05 2025-09-26 天津铭瑞医药科技有限公司 用于治疗高脂血症的中西药物组合

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2903558C2 (de) * 1978-02-03 1994-09-01 Sigma Tau Ind Farmaceuti Verwendung von L-Carnitin
IT1277953B1 (it) * 1995-12-21 1997-11-12 Sigma Tau Ind Farmaceuti Composizione farmaceutica contenente l-carnitina o una alcanoil l- carnitina e un acido poliinsaturo della serie 3-omega utile per
JP3926888B2 (ja) * 1997-05-27 2007-06-06 株式会社カネカ コレステロール低下剤
ITRM20030178A1 (it) 2003-04-17 2004-10-18 Sigma Tau Ind Farmaceuti Uso della l-carnitina per il trattamento di patologie cardiovascolari.
KR101573316B1 (ko) * 2004-03-29 2015-12-01 와이어쓰 엘엘씨 종합비타민 및 무기물 영양 보충제
US20100119600A1 (en) * 2007-06-01 2010-05-13 Joar Opheim Substances for reducing occurrence of major cardiac events comprising red yeast rice extract and omega-3 polyunsaturated fatty acid or derivative thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DAVID J. BECKER et al, ‘Simvastatin vs Therapeutic Lifestyle Changes and Supplements: Randomized Primary Prevention Trial’, Mayo Clin Proc. 2008;83(7):758-764*

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220069174A (ko) * 2020-11-19 2022-05-27 한국식품산업클러스터진흥원 천연 복합물을 포함하는 비만 예방 또는 치료용 조성물
KR102418383B1 (ko) 2020-11-19 2022-07-07 한국식품산업클러스터진흥원 천연 복합물을 포함하는 비만 예방 또는 치료용 조성물

Also Published As

Publication number Publication date
AU2012251818A1 (en) 2013-11-28
CL2013003144A1 (es) 2014-07-04
PH12013502229A1 (en) 2021-06-23
SI2704734T1 (sl) 2015-08-31
JP2014514340A (ja) 2014-06-19
NZ617641A (en) 2015-12-24
EA025256B1 (ru) 2016-12-30
UA112182C2 (uk) 2016-08-10
CN103517711A (zh) 2014-01-15
HRP20150767T1 (hr) 2015-08-28
MY176018A (en) 2020-07-21
CA2834173A1 (en) 2012-11-08
SG194679A1 (en) 2013-12-30
IL229205A (en) 2017-01-31
EP2704734B1 (en) 2015-06-17
EA201391622A1 (ru) 2014-02-28
MX361038B (es) 2018-11-26
RS54100B1 (sr) 2015-10-30
ES2542412T3 (es) 2015-08-05
AU2012251818B2 (en) 2017-04-13
EP2704734A1 (en) 2014-03-12
PL2704734T3 (pl) 2015-10-30
AR086231A1 (es) 2013-11-27
KR20140036170A (ko) 2014-03-25
DK2704734T3 (en) 2015-07-20
US9125903B2 (en) 2015-09-08
CN103517711B (zh) 2016-07-27
IL229205A0 (en) 2014-01-30
PT2704734E (pt) 2015-09-07
CY1116612T1 (el) 2017-03-15
US20140086985A1 (en) 2014-03-27
SMT201500173B (it) 2015-10-30
WO2012150146A1 (en) 2012-11-08
MX2013012781A (es) 2013-12-06
ME02180B (me) 2015-10-20
ZA201309205B (en) 2015-04-29

Similar Documents

Publication Publication Date Title
KR101840082B1 (ko) 지질 대사 장애의 치료에 유용한 조성물
EP1773312B1 (en) Composition containing statins and omega-3 fatty acids
US8895079B2 (en) Combinations of botanical extracts for promoting cardiovascular health
EP2007429B1 (en) Oral formulation with beneficial cardiovascular effects, comprising berberine
US20080107638A1 (en) Methods of attenuating autoimmune disease and compositions useful therefor
US20090214682A1 (en) Composition and methods for weight loss in a subject
TW201300119A (zh) 用於治療脂質代謝失調之組成物
HK1188933A (en) Composition useful for the treatment of lipid metabolism disorders
HK1188933B (en) Composition useful for the treatment of lipid metabolism disorders
JP4929576B2 (ja) 脂質代謝改善剤
KR20120114790A (ko) 정향 에탄올 추출물의 용매 분획물을 유효성분으로 함유하는 고지혈증 예방 및 치료용 지질개선제
HK1105871B (en) Composition containing statins and omega-3 fatty acids
MXPA99011665A (en) Pharmaceutical compositions comprising alkanoyl l-carnitine in combination with a statine for treating pathologies brought about by an altered lipid metabolism

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R11-asn-PN2301

St.27 status event code: A-3-3-R10-R13-asn-PN2301

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PC1903 Unpaid annual fee

Not in force date: 20210314

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

St.27 status event code: A-4-4-U10-U13-oth-PC1903

PC1903 Unpaid annual fee

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20210314

St.27 status event code: N-4-6-H10-H13-oth-PC1903

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000